639 reports of this reaction
3.3% of all RIMEGEPANT SULFATE reports
#5 most reported adverse reaction
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is the #5 most commonly reported adverse reaction for RIMEGEPANT SULFATE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 639 FDA adverse event reports linking RIMEGEPANT SULFATE to THERAPEUTIC PRODUCT EFFECT INCOMPLETE. This represents approximately 3.3% of all 19,247 adverse event reports for this drug.
Patients taking RIMEGEPANT SULFATE who experience therapeutic product effect incomplete should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is moderately reported among RIMEGEPANT SULFATE users, representing a notable but not dominant share of adverse events.
In addition to therapeutic product effect incomplete, the following adverse reactions have been reported for RIMEGEPANT SULFATE:
The following drugs have also been linked to therapeutic product effect incomplete in FDA adverse event reports:
THERAPEUTIC PRODUCT EFFECT INCOMPLETE has been reported as an adverse event in 639 FDA reports for RIMEGEPANT SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE accounts for approximately 3.3% of all adverse event reports for RIMEGEPANT SULFATE, making it a notable side effect.
If you experience therapeutic product effect incomplete while taking RIMEGEPANT SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.